Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors
The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).Orphan medicinal product designation by the EC may provide certain development
Perspective Therapeutics got official approval from Europe to develop a special medicine for a rare cancer. This is a good sign that their drug might be on the right path, so it's worth watching how the treatment tests go next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.